ECRIN is pleased to announce that a new article has been published in The Lancet Gastroenterology & Hepatology entitled 'Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial'.
The LIVERHOPE-SAFETY trial is one of two randomized double-blind trials supported by ECRIN and conducted as part of the Horizon 2020-funded LIVERHOPE project (the other trial is 'LIVERHOPE-EFFICACY').
The aim of LIVERHOPE-SAFETY (as the aforementioned publication title implies) is to investigate the safety and tolerability of a combination of simvastatin plus rifaximin in patients with decompensated cirrhosis in six European countries (Germany, France, Italy, Spain, The Netherlands, and the United Kingdom).
The main objective of the LIVERHOPE project is to improve patients' quality-of-life and to increase survival of patients.
The LIVERHOPE project is supported through the H2020 Societal Challenges (Health, demographic change and well-being) programme under grant agreement number 731875.